Literature DB >> 1164815

Elimination of antipyrine from saliva as a measure of metabolism in man.

R M Welch, R L DeAngelis, M Wingfield, T W Farmer.   

Abstract

The salivary half-life of antipyrine was used as a convenient procedure for estimating the relative rates of drug metabolism in man. The concentration ratio of antipyrine in plasma and saliva was one over a 24-hr period following the oral or parenteral administration of the drug to man and rat. Phenobarbital, a known stimulator of drug metabolism in animals and man, increased markedly the elimination of antipyrine from saliva of rats, while SKF-525A, a potent inhibitor of drug metabolism, prolonged the elimination of antipyrine from rat saliva. In addition, the known sex difference in the metabolism of drugs in the rat was detected by measuring the elimination rate of antipyrine from saliva of male and female rats. The clinical application of the procedure indicated that a group of epileptic patients treated with anticonvulsants for more than 2 mo had a mean antipyrine salivary half-life of 4 hr, whereas a mean half-life of 13 hr was found in a group of normal volunteers. The results show that the elimination rate of antipyrine from saliva is a useful index of drug metabolism in animals and man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1164815     DOI: 10.1002/cpt1975183249

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.

Authors:  A el-Yazigi; D A Raines; H Ali; J Sieck; P Ernst; M Dossing
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

5.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

6.  Antipyrine and metronidazole metabolism during occupational exposure to gasoline.

Authors:  M Døssing; S Loft; J Sonne; E Schroeder
Journal:  Int Arch Occup Environ Health       Date:  1988       Impact factor: 3.015

7.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

8.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 9.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

10.  Impairment of hepatic drug metabolism in alcoholics.

Authors:  A W Harman; D B Frewin; B G Priestly; C B Alexander
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.